Literature DB >> 12372708

Surprise phase III failure for ZD1839.

Emma Wilkinson.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12372708     DOI： 10.1016/s1470-2045(02)00883-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

Review 1.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

2.  Review of the treatment of non-small cell lung cancer with gefitinib.

Authors:  Takuya Araki; Hideaki Yashima; Kimihiro Shimizu; Tohru Aomori; Tadahiro Hashita; Kyoichi Kaira; Tomonori Nakamura; Koujirou Yamamoto
Journal:  Clin Med Insights Oncol       Date:  2012-12-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.